Advances in Latent Tuberculosis Testing and Changing Guidelines

Tuesday, August 6, 6 – 7:30 p.m.
Anaheim Marriott, Platinum Ballroom 6
Supported by DiaSorin, Inc.


Panel presentation discussing the current landscape and latest developments in latent tuberculosis infection (LTBI) testing needs, guidelines, and diagnostics. The "Who, Why, What and How" of LTBI testing in the modern laboratory.


Attendees will:

  • Understand the current latent tuberculosis testing guidelines, including recent updates to health care personnel recommendations.
  • Understand the current diagnostic methods available, and the benefits and limitations of each.
  • Get a preview of upcoming assays and operational improvements.


Greta Schwichtenberg
Sr. Market Development Manager QuantiFERON TB
DiaSorin Inc.
Stillwater, MN


Dr. Masae Kawamura
QIAGEN - Sr. Director Medical and Scientific Affairs
Topic: Latent Tuberculosis Diagnostics Landscape, Changing Guidelines, and Laboratory Automation

Dr. Nicole Green
LA County Public Health
Topic: Latent Tuberculosis Diagnostics Landscape and the Laboratory: Method Review and How These Methods Measure Up

Dr. Marie-Claire Rowlinson
UF Health
Topic: IGRA: Recent Updates in TB Testing and Public Health Programmatic Impact

(Presentation of the QIAGEN/DiaSorin partnership and the LIAISON QFT Solution)